Scholarlink

<p>Resveratrol is a natural compound with notable health benefits, such as anti-inflammatory, antioxidant, and chemopreventive properties. It has shown potential in inhibiting tumorigenesis and tumour progression via targeted therapy, specifically by targeting cancer stem cells (CSCs). CSCs are a small, self-renewing subpopulation within tumours that drive cancer progression and are marked by biomarker proteins such as CD133, CD44, Sox2, Nanog, Oct4, ABCG2 and ALDH1. Effective treatment requires direct targeting of these cells. Understanding the pathways that govern CSC formation and their response to resveratrol is crucial for optimizing therapy. While extensive research exists on resveratrol’s effects in cancers like glioblastoma, breast, and colorectal, studies on its effects in lung cancer stem cells (LCSC) remain limited. This review aims to fill this gap by exploring resveratrol's impact on CSC across various cancers and hypothesizing its mechanisms in lung cancer stem cells (LCSC). By synthesizing findings from other cancer types, we aim to outline potential pathways resveratrol may target in lung CSC as well as to elucidate any interconnectedness between these signalling pathways.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring resveratrol’s inhibitory potential on lung cancer stem cells: a scoping review of mechanistic pathways across cancer models

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月10日

查看全文
  • Alisa Raihana Saiful Hakim,
  • Chin Fei Chee,
  • Tin Wui Wong,
  • Noor Hayaty Abu Kasim,
  • Nurrul Shaqinah Nasruddin,
  • Farinawati Yazid

摘要

Resveratrol is a natural compound with notable health benefits, such as anti-inflammatory, antioxidant, and chemopreventive properties. It has shown potential in inhibiting tumorigenesis and tumour progression via targeted therapy, specifically by targeting cancer stem cells (CSCs). CSCs are a small, self-renewing subpopulation within tumours that drive cancer progression and are marked by biomarker proteins such as CD133, CD44, Sox2, Nanog, Oct4, ABCG2 and ALDH1. Effective treatment requires direct targeting of these cells. Understanding the pathways that govern CSC formation and their response to resveratrol is crucial for optimizing therapy. While extensive research exists on resveratrol’s effects in cancers like glioblastoma, breast, and colorectal, studies on its effects in lung cancer stem cells (LCSC) remain limited. This review aims to fill this gap by exploring resveratrol's impact on CSC across various cancers and hypothesizing its mechanisms in lung cancer stem cells (LCSC). By synthesizing findings from other cancer types, we aim to outline potential pathways resveratrol may target in lung CSC as well as to elucidate any interconnectedness between these signalling pathways.